Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Paradoxical inhibition of insulin secretion by glucose in non-insulin-dependent diabetic patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Permeability of small vessels in diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Tattoos and skin barrier function: Measurements of TEWL, stratum corneum conductance and capacitance, pH, and filaggrin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
A 59-year old man with moderate and stable psoriasis through 15 years was admitted to our Department with inadequately controlled type 2 diabetes. Treatment was initiated with the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide. The patient experienced marked improvement in his psoriasis immediately after the start of liraglutide treatment. Itching stopped within days, scaling was reduced and spots of normal skin emerged. After 3 months, psoriasis was still improving. Excellent glycaemic control and a weight loss of approximately 8 kg over 3 months were moreover obtained. The patient had previously been well controlled in his diabetes without improvement in psoriasis, and the effect of liraglutide on psoriasis started before weight loss occurred. We discuss the possibility of a direct anti-inflammatory effect of liraglutide in psoriasis as well as indirect effects through improvement in comorbidities such as overweight. Randomized clinical trials are needed to reveal whether GLP-1R agonists represent a new therapeutic option for psoriasis.
OriginalsprogEngelsk
TidsskriftActa Diabetologica
ISSN0940-5429
DOI
StatusUdgivet - 2011

ID: 33133098